Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SNY crawled date : 2022 - 02 - 18 save search
Global Bladder Cancer Drug Market (2021 to 2026) - Unhygienic Workplace Exposure and Increase in Smoking Habits is Driving Growth
Published: 2022-02-18 (Crawled : 21:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
bladder cancer drug work cancer drug cancer growth bladder
$26.7 Billion Adult Vaccine Market Outlook, 2027 Featuring Key Players - GSK, Merck & Co, Sanofi Pasteur, Pfizer, and CSL Limited
Published: 2022-02-18 (Crawled : 19:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
vaccine
OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Board of Directors
Published: 2022-02-18 (Crawled : 18:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
ces therapeutics
Sanofi, Regeneron Suffer Rare Dupixent Flop in CSU
Published: 2022-02-18 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
rare dupixent
With Market Size Valued at $6.5 Billion by 2026, it`s a Healthy Outlook for the Global Throat Lozenges Market
Published: 2022-02-18 (Crawled : 16:00) - prnewswire.com
RBGPF | $51.61 6.46% 4.7K
|
Consumer Non-Durables
|
| O: 3.87%
H: 0.0%
C: -3.44%
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.14%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
RBGLY | $10.35 -2.05% 990K
|
Manufacturing
|
| O: 3.3%
H: 0.4%
C: -0.97%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.46%
H: 0.46%
C: -0.19%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
health
BioSpace Movers & Shakers, Feb. 18
Published: 2022-02-18 (Crawled : 14:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
VXRT | News | $0.7652 -9.15% -10.08% 1.9M
|
Health Technology
|
| O: 0.0%
H: 2.95%
C: 0.21%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -1.89%
H: 1.47%
C: -4.21%
ALEC | $5.1 0.2% 0.2% 470K
|
Health Technology
|
| O: -0.37%
H: 3.37%
C: 2.06%
space spac
Azurity Pharmaceuticals Announces Richard Blackburn as New CEO
Published: 2022-02-18 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
als ces new ceo ceo
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Published: 2022-02-18 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
BioArctic continues to build its commercial organization
Published: 2022-02-18 (Crawled : 08:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
commercialization
Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
Published: 2022-02-18 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.